Generating drug resistance models in human and murine cancer cell lines and assessing cross-resistance to chemotherapeutics and KRAS inhibitors Authors: Nicole Martinez, Maria Fumagalli, Ravindra Gujar, Lev Becker, Chang Cui Published: 2026 ABSTRACT SummaryDrug resistance and cross-resistance limit the durability of cancer therapies, yet reproducible in vitro techniques for generating resistant models remain limited. Here, we present a protocol for generating human and murine cancer cell lines with drug resistance to chemotherapeutics and KRAS inhibitors. We describe steps for generating, expanding, and maintaining resistant cells. We then detail procedures for validating drug resistance and cross-resistance, followed by a quantitative killing assay. This approach facilitates the evaluation of resistance and cross-resistance liabilities of compounds.For complete details on the use and execution of this protocol, please refer to Gujar et al.1 Before you begin Acquired resistance1 to cancer therapies is a major clinical challenge that limits the durability of treatment responses.2,3 Resistance to an initial therapy is often accompanied by the emergence of cross-resistance, wherein resistance to one treatment is accompanied by reduced sensitivity to other therapies, often within the same drug class or targeting related pathways.3,4 Although a variety of in vitro approaches have been used to study drug resistance,5 fewer systems are designed to model drug resistance, and potentially acquired resistance with follow up validation work, in a manner that supports systematic evaluation of cross-resistance and downstream mechanistic studies under standardized conditions. To address this gap, this protocol was developed and validated using four chemotherapeutics – doxorubicin, oxaliplatin, paclitaxel, and carboplatin – and two KRAS inhibitors, AMG-510 (KRAS G12C) and MRTX1133 (KRAS G12D), across multiple human and murine cancer cell lines. These agents were chosen because of their widespread clinical use,6,7 the predominance of tumor cell-intrinsic resistance mechanisms,8,9,10,11 and the frequent observation of cross-resistance following treatment failure.8,12 The protocol outlines a generalized in vitro framework for inducing drug resistance through five cycles of drug exposure at defined concentrations, coupled with systematic monitoring of cell survival and recovery. Detailed guidance is provided for treatment cycling, dose adjustment, recovery assessment, criteria for successful resistance establishment, and standardized killing assays to quantify both resistance and cross-resistance. Resistant cell populations generated using this approach are immediately suitable for downstream analyses. It should be noted that the model systems described are drug-resistant, encompassing both intrinsic and acquired resistance. Follow-up validation such as clonal analysis or mutational profiling is required to confirm acquired resistance specifically. Using this framework, we show that chemotherapies or KRAS inhibitors reproducibly induce drug resistance in murine and human cancer cells, typically within five treatment cycles. Moreover, chemotherapeutic- or KRAS inhibitor-resistant cell lines exhibited resistance to other agents within the same drug class, recapitulating clinically observed patterns of cross-resistance1 and validating the use of this system for cross-resistance assessment. In contrast, N17350, a therapeutic elastase, did not induce resistance under the same conditions, and its efficacy was not affected by cross-resistance to other therapeutic modalities.1 Although broadly applicable, the rate and magnitude of resistance development may vary depending on the cell line, therapeutic agent, and dosing strategy. While several observable features during resistance generation may indicate a trajectory toward acquired resistance, appropriate follow-up validation is required for confirmation. Accordingly, critical notes throughout the protocol highlight parameters that may require optimization for specific experimental contexts. Innovation This protocol establishes a standardized in vitro framework that directly couples drug resistance generation with cross-resistance testing. Unlike prior approaches that treat resistance as a terminal endpoint or focus on single agents, this method creates a drug-resistant model as a reusable experimental state that can be interrogated across therapies. A key innovation is the integration of resistance generation and cross-resistance assessment within a unified workflow. By defining reproducible treatment cycles, recovery criteria, and resistance validation benchmarks, the protocol generates stable resistant cell populations that can be directly challenged with secondary agents using standardized killing assays. This enables direct evaluation of whether resistance to a primary therapy confers cross-resistance to related or mechanistically distinct compounds under matched selection pressures. Importantly, because the R5 populations may encompass both intrinsic and acquired resistance mechanisms, this protocol also serves as a versatile entry point for researchers seeking to study either resistance type with the option to apply downstream clonal or mutational analyses to further dissect the underlying biology. Preparation 1: Thaw and expand frozen cells Timing: ∼30 min 1.Thaw frozen cell vials.a.Retrieve frozen vials from liquid nitrogen tank.b.Immediately place the vial on a floater in a 37°C water bath.c.Thaw for approximately 1–3 min. Note: Avoid over-thawing; prolonged exposure to cryoprotective agents present in the freezing medium reduces viability. 2.Wash cells.a.Spray the vial with 70% ethanol and transfer contents to a labeled 15 mL conical tube.b.Using a P1000, gently pipet up and down to break aggregates.c.Add growth media to thawed cell suspension to reach a total volume of 10 mL.d.Centrifuge at 300 × g for 5 min.Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction.Note: All subsequent cell handling steps should be performed inside a certified biosafety cabinet using standard aseptic technique to maintain sterility and prevent contamination.e.Aspirate the supernatant.CRITICAL: This wash step removes DMSO or other cell freezing reagents, which could be toxic if insufficiently removed.3.Cell Counting.a.Resuspend the pellet in 1mL of full growth media with a P1000 pipette.b.Count cells and determine cell viability and concentrations.c.If the cell concentration is greater than 1 × 106 use a 75 cm2 tissue (T75) -culture flask; if it is less than 1 × 106, use a 25 cm2 tissue (T25) -culture flask.4.Cell plating.a.Add an appropriate volume of pre-warmed media to the tissue culture flask.b.Transfer the 1mL cell suspension to a tissue culture treated flask.c.Incubate at 37°C with 5% CO2.d.Replace media every 3 days until cell cultures reach approximately 80%–90% confluency.Figure 1Example of cell plating layoutRepresentative 12-well plate layout showing the suggested arrangement of treatment and control wells. Rows A–C and columns 1–4 indicate well positions within the plate. Rows A and B contain duplicate wells (Rep1 and Rep2) for three different drug treatment conditions (Drug X, Drug Y, and Drug Z). Row C and well B4 contain passage-matched control cells (P1–P5) plated at one-tenth the seeding density in full growth medium. Arrows indicate the suggested passage order for control cells. Note: All cell lines used in this study were maintained at 5% CO2. However, CO2 requirements may vary depending on the cell line. Researchers should consult the supplier's recommendations or established culture conditions for their specific cell line before proceeding. Timing: ∼30 min 1.Thaw frozen cell vials.a.Retrieve frozen vials from liquid nitrogen tank.b.Immediately place the vial on a floater in a 37°C water bath.c.Thaw for approximately 1–3 min. Thaw frozen cell vials.a.Retrieve frozen vials from liquid nitrogen tank.b.Immediately place the vial on a floater in a 37°C water bath.c.Thaw for approximately 1–3 min. a.Retrieve frozen vials from liquid nitrogen tank. Retrieve frozen vials from liquid nitrogen tank. b.Immediately place the vial on a floater in a 37°C water bath. Immediately place the vial on a floater in a 37°C water bath. c.Thaw for approximately 1–3 min. Thaw for approximately 1–3 min. Note: Avoid over-thawing; prolonged exposure to cryoprotective agents present in the freezing medium reduces viability. 2.Wash cells.a.Spray the vial with 70% ethanol and transfer contents to a labeled 15 mL conical tube.b.Using a P1000, gently pipet up and down to break aggregates.c.Add growth media to thawed cell suspension to reach a total volume of 10 mL.d.Centrifuge at 300 × g for 5 min.Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction.Note: All subsequent cell handling steps should be performed inside a certified biosafety cabinet using standard aseptic technique to maintain sterility and prevent contamination.e.Aspirate the supernatant.CRITICAL: This wash step removes DMSO or other cell freezing reagents, which could be toxic if insufficiently removed. Wash cells.a.Spray the vial with 70% ethanol and transfer contents to a labeled 15 mL conical tube.b.Using a P1000, gently pipet up and down to break aggregates.c.Add growth media to thawed cell suspension to reach a total volume of 10 mL.d.Centrifuge at 300 × g for 5 min.Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction.Note: All subsequent cell handling steps should be performed inside a certified biosafety cabinet using standard aseptic technique to maintain sterility and prevent contamination.e.Aspirate the supernatant.CRITICAL: This wash step removes DMSO or other cell freezing reagents, which could be toxic if insufficiently removed. a.Spray the vial with 70% ethanol and transfer contents to a labeled 15 mL conical tube. Spray the vial with 70% ethanol and transfer contents to a labeled 15 mL conical tube. b.Using a P1000, gently pipet up and down to break aggregates. Using a P1000, gently pipet up and down to break aggregates. c.Add growth media to thawed cell suspension to reach a total volume of 10 mL. Add growth media to thawed cell suspension to reach a total volume of 10 mL. d.Centrifuge at 300 × g for 5 min.Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction.Note: All subsequent cell handling steps should be performed inside a certified biosafety cabinet using standard aseptic technique to maintain sterility and prevent contamination. Centrifuge at 300 × g for 5 min.Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction.Note: All subsequent cell handling steps should be performed inside a certified biosafety cabinet using standard aseptic technique to maintain sterility and prevent contamination. Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction. Note: All subsequent cell handling steps should be performed inside a certified biosafety cabinet using standard aseptic technique to maintain sterility and prevent contamination. e.Aspirate the supernatant.CRITICAL: This wash step removes DMSO or other cell freezing reagents, which could be toxic if insufficiently removed. Aspirate the supernatant.CRITICAL: This wash step removes DMSO or other cell freezing reagents, which could be toxic if insufficiently removed. CRITICAL: This wash step removes DMSO or other cell freezing reagents, which could be toxic if insufficiently removed. 3.Cell Counting.a.Resuspend the pellet in 1mL of full growth media with a P1000 pipette.b.Count cells and determine cell viability and concentrations.c.If the cell concentration is greater than 1 × 106 use a 75 cm2 tissue (T75) -culture flask; if it is less than 1 × 106, use a 25 cm2 tissue (T25) -culture flask. Cell Counting.a.Resuspend the pellet in 1mL of full growth media with a P1000 pipette.b.Count cells and determine cell viability and concentrations.c.If the cell concentration is greater than 1 × 106 use a 75 cm2 tissue (T75) -culture flask; if it is less than 1 × 106, use a 25 cm2 tissue (T25) -culture flask. a.Resuspend the pellet in 1mL of full growth media with a P1000 pipette. Resuspend the pellet in 1mL of full growth media with a P1000 pipette. b.Count cells and determine cell viability and concentrations. Count cells and determine cell viability and concentrations. c.If the cell concentration is greater than 1 × 106 use a 75 cm2 tissue (T75) -culture flask; if it is less than 1 × 106, use a 25 cm2 tissue (T25) -culture flask. If the cell concentration is greater than 1 × 106 use a 75 cm2 tissue (T75) -culture flask; if it is less than 1 × 106, use a 25 cm2 tissue (T25) -culture flask. 4.Cell plating.a.Add an appropriate volume of pre-warmed media to the tissue culture flask.b.Transfer the 1mL cell suspension to a tissue culture treated flask.c.Incubate at 37°C with 5% CO2.d.Replace media every 3 days until cell cultures reach approximately 80%–90% confluency.Figure 1Example of cell plating layoutRepresentative 12-well plate layout showing the suggested arrangement of treatment and control wells. Rows A–C and columns 1–4 indicate well positions within the plate. Rows A and B contain duplicate wells (Rep1 and Rep2) for three different drug treatment conditions (Drug X, Drug Y, and Drug Z). Row C and well B4 contain passage-matched control cells (P1–P5) plated at one-tenth the seeding density in full growth medium. Arrows indicate the suggested passage order for control cells. Cell plating.a.Add an appropriate volume of pre-warmed media to the tissue culture flask.b.Transfer the 1mL cell suspension to a tissue culture treated flask.c.Incubate at 37°C with 5% CO2.d.Replace media every 3 days until cell cultures reach approximately 80%–90% confluency.Figure 1Example of cell plating layoutRepresentative 12-well plate layout showing the suggested arrangement of treatment and control wells. Rows A–C and columns 1–4 indicate well positions within the plate. Rows A and B contain duplicate wells (Rep1 and Rep2) for three different drug treatment conditions (Drug X, Drug Y, and Drug Z). Row C and well B4 contain passage-matched control cells (P1–P5) plated at one-tenth the seeding density in full growth medium. Arrows indicate the suggested passage order for control cells. a.Add an appropriate volume of pre-warmed media to the tissue culture flask. Add an appropriate volume of pre-warmed media to the tissue culture flask. b.Transfer the 1mL cell suspension to a tissue culture treated flask. Transfer the 1mL cell suspension to a tissue culture treated flask. c.Incubate at 37°C with 5% CO2. Incubate at 37°C with 5% CO2. d.Replace media every 3 days until cell cultures reach approximately 80%–90% confluency.Figure 1Example of cell plating layoutRepresentative 12-well plate layout showing the suggested arrangement of treatment and control wells. Rows A–C and columns 1–4 indicate well positions within the plate. Rows A and B contain duplicate wells (Rep1 and Rep2) for three different drug treatment conditions (Drug X, Drug Y, and Drug Z). Row C and well B4 contain passage-matched control cells (P1–P5) plated at one-tenth the seeding density in full growth medium. Arrows indicate the suggested passage order for control cells. Replace media every 3 days until cell cultures reach approximately 80%–90% confluency.Figure 1Example of cell plating layoutRepresentative 12-well plate layout showing the suggested arrangement of treatment and control wells. Rows A–C and columns 1–4 indicate well positions within the plate. Rows A and B contain duplicate wells (Rep1 and Rep2) for three different drug treatment conditions (Drug X, Drug Y, and Drug Z). Row C and well B4 contain passage-matched control cells (P1–P5) plated at one-tenth the seeding density in full growth medium. Arrows indicate the suggested passage order for control cells. Example of cell plating layout Representative 12-well plate layout showing the suggested arrangement of treatment and control wells. Rows A–C and columns 1–4 indicate well positions within the plate. Rows A and B contain duplicate wells (Rep1 and Rep2) for three different drug treatment conditions (Drug X, Drug Y, and Drug Z). Row C and well B4 contain passage-matched control cells (P1–P5) plated at one-tenth the seeding density in full growth medium. Arrows indicate the suggested passage order for control cells. Note: All cell lines used in this study were maintained at 5% CO2. However, CO2 requirements may vary depending on the cell line. Researchers should consult the supplier's recommendations or established culture conditions for their specific cell line before proceeding. Preparation 2: Plate cells for resistance induction Timing: ∼1 day 5.Lifting adherent cells.a.Gently aspirate the medium.b.Wash cells with 1× PBS.c.Aspirate PBS.d.Add an appropriate amount of TrypLE to the flask.Note: TrypLE volume will vary depending on flask size. For example, use 2 mL for a T25 flask and 5 mL for a T75 flask, ensuring the entire cell monolayer is covered.Note: Avoid leaving cells in TrypLE for more than 10 min, as viability will begin to decline. Trypsin may be used as an alternative but is harsher; TrypLE is preferred.e.Incubate at 37°C with 5% CO2 for 5 minutes, or longer as needed for the specific cell type.f.Gently tap the side of the flask to detach cells.g.Add appropriate volume of full growth media to neutralize TrypLE.h.Transfer the cell suspension to a labeled conical tube.i.Centrifuge at 300 × g for 5 minutes.Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction.j.Aspirate supernatant.6.Plating Cells.a.Add 1 mL of full growth media with a P1000 pipette and gently pipet up and down to break aggregates.b.Add an appropriate volume of full growth media based on size of cell pellet.c.Count cells and determine cell viability and concentrations.d.Plate 0.1–0.2 × 106 viable cells in 2 mL per well in a 12-well plate in duplicate for each treatment condition.Note: Plating density should be adjusted based on the growth rate of each cell line to ensure cultures reach approximately 90% confluency on the day of drug treatment.CRITICAL: Plate two replicate wells for each treatment condition to ensure at least one well remains available for recovery in the event of complete cell loss during drug treatment cycles (see Step 10).e.In parallel, plate ten-fold fewer cells (0.01–0.02 × 106 cells in 2 mL per well) in a single well as passage-matched control cells. See example of plate layout in Figure 1.Note: Although drug-treated cells are not enzymatically lifted during each recovery phase, they undergo repeated population depletion and subsequent expansion over time. Passage-matched control cells account for biological changes associated with prolonged culture and repeated expansion independent of drug exposure.CRITICAL: Plate fewer control cells so that control cultures remain sub-confluent and can be passaged along with treatment groups undergoing treatment–recovery cycles. Exact plating ratios do not need to be rigidly maintained; adjust based on cell behavior observed during the first cycle to facilitate counting and downstream expansion.f.Incubate cells at 37°C with 5% CO2 until ready for treatment. Timing: ∼1 day 5.Lifting adherent cells.a.Gently aspirate the medium.b.Wash cells with 1× PBS.c.Aspirate PBS.d.Add an appropriate amount of TrypLE to the flask.Note: TrypLE volume will vary depending on flask size. For example, use 2 mL for a T25 flask and 5 mL for a T75 flask, ensuring the entire cell monolayer is covered.Note: Avoid leaving cells in TrypLE for more than 10 min, as viability will begin to decline. Trypsin may be used as an alternative but is harsher; TrypLE is preferred.e.Incubate at 37°C with 5% CO2 for 5 minutes, or longer as needed for the specific cell type.f.Gently tap the side of the flask to detach cells.g.Add appropriate volume of full growth media to neutralize TrypLE.h.Transfer the cell suspension to a labeled conical tube.i.Centrifuge at 300 × g for 5 minutes.Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction.j.Aspirate supernatant. Lifting adherent cells.a.Gently aspirate the medium.b.Wash cells with 1× PBS.c.Aspirate PBS.d.Add an appropriate amount of TrypLE to the flask.Note: TrypLE volume will vary depending on flask size. For example, use 2 mL for a T25 flask and 5 mL for a T75 flask, ensuring the entire cell monolayer is covered.Note: Avoid leaving cells in TrypLE for more than 10 min, as viability will begin to decline. Trypsin may be used as an alternative but is harsher; TrypLE is preferred.e.Incubate at 37°C with 5% CO2 for 5 minutes, or longer as needed for the specific cell type.f.Gently tap the side of the flask to detach cells.g.Add appropriate volume of full growth media to neutralize TrypLE.h.Transfer the cell suspension to a labeled conical tube.i.Centrifuge at 300 × g for 5 minutes.Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction.j.Aspirate supernatant. a.Gently aspirate the medium. Gently aspirate the medium. b.Wash cells with 1× PBS. Wash cells with 1× PBS. c.Aspirate PBS. Aspirate PBS. d.Add an appropriate amount of TrypLE to the flask.Note: TrypLE volume will vary depending on flask size. For example, use 2 mL for a T25 flask and 5 mL for a T75 flask, ensuring the entire cell monolayer is covered.Note: Avoid leaving cells in TrypLE for more than 10 min, as viability will begin to decline. Trypsin may be used as an alternative but is harsher; TrypLE is preferred. Add an appropriate amount of TrypLE to the flask.Note: TrypLE volume will vary depending on flask size. For example, use 2 mL for a T25 flask and 5 mL for a T75 flask, ensuring the entire cell monolayer is covered.Note: Avoid leaving cells in TrypLE for more than 10 min, as viability will begin to decline. Trypsin may be used as an alternative but is harsher; TrypLE is preferred. Note: TrypLE volume will vary depending on flask size. For example, use 2 mL for a T25 flask and 5 mL for a T75 flask, ensuring the entire cell monolayer is covered. Note: Avoid leaving cells in TrypLE for more than 10 min, as viability will begin to decline. Trypsin may be used as an alternative but is harsher; TrypLE is preferred. e.Incubate at 37°C with 5% CO2 for 5 minutes, or longer as needed for the specific cell type. Incubate at 37°C with 5% CO2 for 5 minutes, or longer as needed for the specific cell type. f.Gently tap the side of the flask to detach cells. Gently tap the side of the flask to detach cells. g.Add appropriate volume of full growth media to neutralize TrypLE. Add appropriate volume of full growth media to neutralize TrypLE. h.Transfer the cell suspension to a labeled conical tube. Transfer the cell suspension to a labeled conical tube. i.Centrifuge at 300 × g for 5 minutes.Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction. Centrifuge at 300 × g for 5 minutes.Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction. Note: For fragile cell lines, adjust centrifugation speed and duration according to the cell line instruction. j.Aspirate supernatant. Aspirate supernatant. 6.Plating Cells.a.Add 1 mL of full growth media with a P1000 pipette and gently pipet up and down to break aggregates.b.Add an appropriate volume of full growth media based on size of cell pellet.c.Count cells and determine cell viability and concentrations.d.Plate 0.1–0.2 × 106 viable cells in 2 mL per well in a 12-well plate in duplicate for each treatment condition.Note: Plating density should be adjusted based on the growth rate of each cell line to ensure cultures reach approximately 90% confluency on the day of drug treatment.CRITICAL: Plate two replicate wells for each treatment condition to ensure at least one well remains available for recovery in the event of complete cell loss during drug treatment cycles (see Step 10).e.In parallel, plate ten-fold fewer cells (0.01–0.02 × 106 cells in 2 mL per well) in a single well as passage-matched control cells. See example of plate layout in Figure 1.Note: Although drug-treated cells are not enzymatically lifted during each recovery phase, they undergo repeated population depletion and subsequent expansion over time. Passage-matched control cells account for biological changes associated with prolonged culture and repeated expansion independent of drug exposure.CRITICAL: Plate fewer control cells so that control cultures remain sub-confluent and can be passaged along with treatment groups undergoing treatment–recovery cycles. Exact plating ratios do not need to be rigidly maintained; adjust based on cell behavior observed during the first cycle to facilitate counting and downstream expansion.f.Incubate cells at 37°C with 5% CO2 until ready for treatment. Plating Cells.a.Add 1 mL of full growth media with a P1000 pipette and gently pipet up and down to break aggregates.b.Add an appropriate volume of full growth media based on size of cell pellet.c.Count cells and determine cell viability and concentrations.d.Plate 0.1–0.2 × 106 viable cells in 2 mL per well in a 12-well plate in duplicate for each treatment condition.Note: Plating density should be adjusted based on the growth rate of each cell line to ensure cultures reach approximately 90% confluency on the day of drug treatment.CRITICAL: Plate two replicate wells for each treatment condition to ensure at least one well remains available for recovery in the event of complete cell loss during drug treatment cycles (see Step 10).e.In parallel, plate ten-fold fewer cells (0.01–0.02 × 106 cells in 2 mL per well) in a single well as passage-matched control cells. See example of plate layout in Figure 1.Note: Although drug-treated cells are not enzymatically lifted during each recovery phase, they undergo repeated population depletion and subsequent expansion over time. Passage-matched control cells account for biological changes associated with prolonged culture and repeated expansion independent of drug exposure.CRITICAL: Plate fewer control cells so that control cultures remain sub-confluent and can be passaged along with treatment groups undergoing treatment–recovery cycles. Exact plating ratios do not need to be rigidly maintained; adjust based on cell behavior observed during the first cycle to facilitate counting and downstream expansion.f.Incubate cells at 37°C with 5% CO2 until ready for treatment. a.Add 1 mL of full growth media with a P1000 pipette and gently pipet up and down to break aggregates. Add 1 mL of full growth media with a P1000 pipette and gently pipet up and down to break aggregates. b.Add an appropriate volume of full growth media based on size of cell pellet. Add an appropriate volume of full growth media based on size of cell pellet. c.Count cells and determine cell viability and concentrations. Count cells and determine cell viability and concentrations. d.Plate 0.1–0.2 × 106 viable cells in 2 mL per well in a 12-well plate in duplicate for each treatment condition.Note: Plating density should be adjusted based on the growth rate of each cell line to ensure cultures reach approximately 90% confluency on the day of drug treatment.CRITICAL: Plate two replicate wells for each treatment condition to ensure at least one well remains available for recovery in the event of complete cell loss during drug treatment cycles (see Step 10). Plate 0.1–0.2 × 106 viable cells in 2 mL per well in a 12-well plate in duplicate for each treatment condition.Note: Plating density should be adjusted based on the growth rate of each cell line to ensure cultures reach approximately 90% confluency on the day of drug treatment.CRITICAL: Plate two replicate wells for each treatment condition to ensure at least one well remains available for recovery in the event of complete cell loss during drug treatment cycles (see Step 10). Note: Plating density should be adjusted based on the growth rate of each cell line to ensure cultures reach approximately 90% confluency on the day of drug treatment. CRITICAL: Plate two replicate wells for each treatment condition to ensure at least one well remains available for recovery in the event of complete cell loss during drug treatment cycles (see Step 10). e.In parallel, plate ten-fold fewer cells (0.01–0.02 × 106 cells in 2 mL per well) in a single well as passage-matched control cells. See example of plate layout in Figure 1.Note: Although drug-treated cells are not enzymatically lifted during each recovery phase, they undergo repeated population depletion and subsequent expansion over time. Passage-matched control cells account for biological changes associated with prolonged culture and repeated expansion independent of drug exposure.CRITICAL: Plate fewer control cells so that control cultures remain sub-confluent and can be passaged along with treatment groups undergoing treatment–recovery cycles. Exact plating ratios do not need to be rigidly maintained; adjust based on cell behavior observed during the first cycle to facilitate counting and downstream expansion. In parallel, plate ten-fold fewer cells (0.01–0.02 × 106 cells in 2 mL per well) in a single well as passage-matched control cells. See example of plate layout in Figure 1.Note: Although drug-treated cells are not enzymatically lifted during each recovery phase, they undergo repeated population depletion and subsequent expansion over time. Passage-matched control cells account for biological changes associated with prolonged culture and repeated expansion independent of drug exposure.CRITICAL: Plate fewer control cells so that control cultures remain sub-confluent and can be passaged along with treatment groups undergoing treatment–recovery cycles. Exact plating ratios do not need to be rigidly maintained; adjust based on cell behavior observed during the first cycle to facilitate counting and downstream expansion. Note: Although drug-treated cells are not enzymatically lifted during each recovery phase, they undergo repeated population depletion and subsequent expansion over time. Passage-matched control cells account for biological changes associated with prolonged culture and repeated expansion independent of drug exposure. CRITICAL: Plate fewer control cells so that control cultures remain sub-confluent and can be passaged along with treatment groups undergoing treatment–recovery cycles. Exact plating ratios do not need to be rigidly maintained; adjust based on cell behavior observed during the first cycle to facilitate counting and downstream expansion. f.Incubate cells at 37°C with 5% CO2 until ready for treatment. Incubate cells at 37°C with 5% CO2 until ready for treatment. Key resources table REAGENT or RESOURCESOURCEIDENTIFIERChemicals, peptides, and recombinant proteinsAMG-510MedChemExpressCat#229672-00-3 Lot#159450MRTX1133MedChemExpressCat#HY-134813 Lot#251117CarboplatinSigmaCat#PHR3417; Batch#MKCR3593OxaliplatinSigma AldrichCat#PHR1528; Source# _RAC5719PaclitaxelInvitrogenCat#P3456; Lot#3123565DoxorubicinSelleckchemCat# S1208; Lot#S120816RPMI-1640 MediumGibcoCat#11-875-05Dulbecco's Modified Eagle Medium (DMEM)GibcoCat#11965-092Minimum Essential Medium EagleSigma AldrichCat#M4655Fetal Bovine Serum (FBS)Gemini Bio-ProductsCat#10-082-147Penicillin-StreptomycinGibcoCat#15140-122Sodium PyruvateGibcoCat#11360-070Phosphate Buffered Saline (PBS pH 7.4 (1×))GibcoCat#10010-023Hank’s Balances Salt Solution (HBSS (1×))GibcoCat#14025-076TrypLE ExpressGibcoCat#12605-028Calcein-AM Viability dyeThermoFisher ScientificCat#C1430Experimental models: Cell linesCT26ATCCCat# CRL-2638A549ATCCCat# CCL-185NCI-H358ATCCCat# CRL-5807Hs695TATCCCat# HTB -137NCI-H2122ATCCCat# CRL-5985Software and algorithmsGraphPad Prism v10GraphPadhttps://www.graphpad.com/ scientific-software/prism/Other15mL conical tubeThermoFisher ScientificCat#1256526850mL conical tubeThermoFisher ScientificCat#12565270VarioskanThermoFisher ScientificCat#VLBLA0D0Cytation 5Agilent BioTekCat#BTCYT5FV96 Well clear bottom black TC-treated plateCorningCat#3603 REAGENT or RESOURCESOURCEIDENTIFIERChemicals, peptides, and recombinant proteinsAMG-510MedChemExpressCat#229672-00-3 Lot#159450MRTX1133MedChemExpressCat#HY-134813 Lot#251117CarboplatinSigmaCat#PHR3417; Batch#MKCR3593OxaliplatinSigma AldrichCat#PHR1528; Source# _RAC5719PaclitaxelInvitrogenCat#P3456; Lot#3123565DoxorubicinSelleckchemCat# S1208; Lot#S120816RPMI-1640 MediumGibcoCat#11-875-05Dulbecco's Modified Eagle Medium (DMEM)GibcoCat#11965-092Minimum Essential Medium EagleSigma AldrichCat#M4655Fetal Bovine Serum (FBS)Gemini Bio-ProductsCat#10-082-147Penicillin-StreptomycinGibcoCat#15140-122Sodium PyruvateGibcoCat#11360-070Phosphate Buffered Saline (PBS pH 7.4 (1×))GibcoCat#10010-023Hank’s Balances Salt Solution (HBSS (1×))GibcoCat#14025-076TrypLE ExpressGibcoCat#12605-028Calcein-AM Viability dyeThermoFisher ScientificCat#C1430Experimental models: Cell linesCT26ATCCCat# CRL-2638A549ATCCCat# CCL-185NCI-H358ATCCCat# CRL-5807Hs695TATCCCat# HTB -137NCI-H2122ATCCCat# CRL-5985Software and algorithmsGraphPad Prism v10GraphPadhttps://www.graphpad.com/ scientific-software/prism/Other15mL conical tubeThermoFisher ScientificCat#1256526850mL conical tubeThermoFisher ScientificCat#12565270VarioskanThermoFisher ScientificCat#VLBLA0D0Cytation 5Agilent BioTekCat#BTCYT5FV96 Well clear bottom black TC-treated plateCorningCat#3603 Step-by-step method details Prepare drug for resistance induction Timing: ∼1 h Timing: ∼1 h This section describes the preparation of cytotoxic drug stocks and working dilutions used for resistance induction. Proper reconstitution, storage, and dilution of compounds are critical to ensure consistent selective pressure across treatment cycles.1.Reconstitute drugs.a.Perform all drug preparation in a certified sterile biosafety cabinet.Note: Use appropriate personal protective equipment, as all compounds are cytotoxic.b.Reconstitute each compound to the appropriate stock concentration using the solvent specified in Table 1.c.Aliquot reconstituted stocks and store under the conditions indicated in Table 1 to avoid repeated freeze-thaw cycles.2.Prepare cytotoxic treatment solutions.a.Dilute each drug stock to the starting concentration listed in Table 2 in complete culture medium.CRITICAL: Always prepare fresh dilutions for each treatment cycle; do not reuse diluted drug solutions across cycles.b.Keep diluted starting-dose drug solutions on ice until use.c.Equilibrate diluted drug solutions at 18°C–25°C for 10 min before adding to cells.CRITICAL: Store diluted stocks on ice to maintain stability and equilibrate to 18°C–25°C for 10–15 min prior to treating cells to avoid temperature shock.CRITICAL: For cell lines or compounds not listed in Table 2, we recommend performing a preliminary 72-h dose-response assay prior to resistance induction to determine an appropriate starting concentration. Using the killing assay described in Steps 12–14, identify a concentration that yields approximately 70% cell death, and use this as the starting dose for cycle 1.Table 1Drug reconstitution and storageCytotoxic drugsReconstitute stock concentrationRecommended reconstitution solventLight sensitivity13Storage conditionComments/ Storage lengthDoxorubicin50 mMDMSOYes−20°CUp for 3 monthsPaclitaxel5 mMDMSOYes−20°CUp for 3 monthsCarboplatin22.44 mMH2OYes−80°CDMSO can inactivate its activity; Up for 6 monthsOxaliplatin16 mM5% dextroseYes−80°Cincompatible with chloride-containing solutions; DMSO can inactivate its activity Up for 6 monthsMRTX113310 mMDMSONo−20°CUp for 1 yearAMG-51025 mMDMSONo−20°CUp for 1 yearNote: All solutions should be diluted into aqueous media immediately before use. Carboplatin and Oxaliplatin can be stored under 4°C for up to 2 weeks. Light-sensitive compounds should be stored in amber tube.Table 2Recommended starting doses for resistance inductionCytotoxic drugsRecommended starting dose (cycle 1)Representative cell linesDoxorubicin10 μMCT26–2 μMA549–0.5 μMNCI-H358, Hs695TPaclitaxel10 μMA549, NCI-H358, Hs695T–20 μMCT26Carboplatin50 μMCT26, A549, NCI-H2122, NCI-H358–10 μMHs695TOxaliplatin20 μMCT26, A549, NCI-H2122, NCI-H358–5 μMHs695TMRTX1131 μMCT26AMG-5101 μMNCI-H358Note: The representative cell lines listed are provided as examples only. In practice, some cell lines may fail to develop drug resistance if drug treatment induces rapid and near-complete cell death or causes irreversible morphological changes that impair recovery. It is recommended to begin with lower starting doses and adjust as needed. 1.Reconstitute drugs.a.Perform all drug preparation in a certified sterile biosafety cabinet.Note: Use appropriate personal protective equipment, as all compounds are cytotoxic.b.Reconstitute each compound to the appropriate stock concentration using the solvent specified in Table 1.c.Aliquot reconstituted stocks and store under the conditions indicated in Table 1 to avoid repeated freeze-thaw cycles. Reconstitute drugs.a.Perform all drug preparation in a certified sterile biosafety cabinet.Note: Use appropriate personal protective equipment, as all compounds are cytotoxic.b.Reconstitute each compound to the appropriate stock concentration using the solvent specified in Table 1.c.Aliquot reconstituted stocks and store under the conditions indicated in Table 1 to avoid repeated freeze-thaw cycles. a.Perform all drug preparation in a certified sterile biosafety cabinet.Note: Use appropriate personal protective equipment, as all compounds are cytotoxic. Perform all drug preparation in a certified sterile biosafety cabinet.Note: Use appropriate personal protective equipment, as all compounds are cytotoxic. Note: Use appropriate personal protective equipment, as all compounds are cytotoxic. b.Reconstitute each compound to the appropriate stock concentration using the solvent specified in Table 1. Reconstitute each compound to the appropriate stock concentration using the solvent specified in Table 1. c.Aliquot reconstituted stocks and store under the conditions indicated in Table 1 to avoid repeated freeze-thaw cycles. Aliquot reconstituted stocks and store under the conditions indicated in Table 1 to avoid repeated freeze-thaw cycles. 2.Prepare cytotoxic treatment solutions.a.Dilute each drug stock to the starting concentration listed in Table 2 in complete culture medium.CRITICAL: Always prepare fresh dilutions for each treatment cycle; do not reuse diluted drug solutions across cycles.b.Keep diluted starting-dose drug solutions on ice until use.c.Equilibrate diluted drug solutions at 18°C–25°C for 10 min before adding to cells.CRITICAL: Store diluted stocks on ice to maintain stability and equilibrate to 18°C–25°C for 10–15 min prior to treating cells to avoid temperature shock.CRITICAL: For cell lines or compounds not listed in Table 2, we recommend performing a preliminary 72-h dose-response assay prior to resistance induction to determine an appropriate starting concentration. Using the killing assay described in Steps 12–14, identify a concentration that yields approximately 70% cell death, and use this as the starting dose for cycle 1. Prepare cytotoxic treatment solutions.a.Dilute each drug stock to the starting concentration listed in Table 2 in complete culture medium.CRITICAL: Always prepare fresh dilutions for each treatment cycle; do not reuse diluted drug solutions across cycles.b.Keep diluted starting-dose drug solutions on ice until use.c.Equilibrate diluted drug solutions at 18°C–25°C for 10 min before adding to cells.CRITICAL: Store diluted stocks on ice to maintain stability and equilibrate to 18°C–25°C for 10–15 min prior to treating cells to avoid temperature shock.CRITICAL: For cell lines or compounds not listed in Table 2, we recommend performing a preliminary 72-h dose-response assay prior to resistance induction to determine an appropriate starting concentration. Using the killing assay described in Steps 12–14, identify a concentration that yields approximately 70% cell death, and use this as the starting dose for cycle 1. a.Dilute each drug stock to the starting concentration listed in Table 2 in complete culture medium.CRITICAL: Always prepare fresh dilutions for each treatment cycle; do not reuse diluted drug solutions across cycles. Dilute each drug stock to the starting concentration listed in Table 2 in complete culture medium.CRITICAL: Always prepare fresh dilutions for each treatment cycle; do not reuse diluted drug solutions across cycles. CRITICAL: Always prepare fresh dilutions for each treatment cycle; do not reuse diluted drug solutions across cycles. b.Keep diluted starting-dose drug solutions on ice until use. Keep diluted starting-dose drug solutions on ice until use. c.Equilibrate diluted drug solutions at 18°C–25°C for 10 min before adding to cells.CRITICAL: Store diluted stocks on ice to maintain stability and equilibrate to 18°C–25°C for 10–15 min prior to treating cells to avoid temperature shock.CRITICAL: For cell lines or compounds not listed in Table 2, we recommend performing a preliminary 72-h dose-response assay prior to resistance induction to determine an appropriate starting concentration. Using the killing assay described in Steps 12–14, identify a concentration that yields approximately 70% cell death, and use this as the starting dose for cycle 1. Equilibrate diluted drug solutions at 18°C–25°C for 10 min before adding to cells.CRITICAL: Store diluted stocks on ice to maintain stability and equilibrate to 18°C–25°C for 10–15 min prior to treating cells to avoid temperature shock.CRITICAL: For cell lines or compounds not listed in Table 2, we recommend performing a preliminary 72-h dose-response assay prior to resistance induction to determine an appropriate starting concentration. Using the killing assay described in Steps 12–14, identify a concentration that yields approximately 70% cell death, and use this as the starting dose for cycle 1. CRITICAL: Store diluted stocks on ice to maintain stability and equilibrate to 18°C–25°C for 10–15 min prior to treating cells to avoid temperature shock. CRITICAL: For cell lines or compounds not listed in Table 2, we recommend performing a preliminary 72-h dose-response assay prior to resistance induction to determine an appropriate starting concentration. Using the killing assay described in Steps 12–14, identify a concentration that yields approximately 70% cell death, and use this as the starting dose for cycle 1. Table 1Drug reconstitution and storageCytotoxic drugsReconstitute stock concentrationRecommended reconstitution solventLight sensitivity13Storage conditionComments/ Storage lengthDoxorubicin50 mMDMSOYes−20°CUp for 3 monthsPaclitaxel5 mMDMSOYes−20°CUp for 3 monthsCarboplatin22.44 mMH2OYes−80°CDMSO can inactivate its activity; Up for 6 monthsOxaliplatin16 mM5% dextroseYes−80°Cincompatible with chloride-containing solutions; DMSO can inactivate its activity Up for 6 monthsMRTX113310 mMDMSONo−20°CUp for 1 yearAMG-51025 mMDMSONo−20°CUp for 1 yearNote: All solutions should be diluted into aqueous media immediately before use. Carboplatin and Oxaliplatin can be stored under 4°C for up to 2 weeks. Light-sensitive compounds should be stored in amber tube. Drug reconstitution and storage Note: All solutions should be diluted into aqueous media immediately before use. Carboplatin and Oxaliplatin can be stored under 4°C for up to 2 weeks. Light-sensitive compounds should be stored in amber tube. Table 2Recommended starting doses for resistance inductionCytotoxic drugsRecommended starting dose (cycle 1)Representative cell linesDoxorubicin10 μMCT26–2 μMA549–0.5 μMNCI-H358, Hs695TPaclitaxel10 μMA549, NCI-H358, Hs695T–20 μMCT26Carboplatin50 μMCT26, A549, NCI-H2122, NCI-H358–10 μMHs695TOxaliplatin20 μMCT26, A549, NCI-H2122, NCI-H358–5 μMHs695TMRTX1131 μMCT26AMG-5101 μMNCI-H358Note: The representative cell lines listed are provided as examples only. In practice, some cell lines may fail to develop drug resistance if drug treatment induces rapid and near-complete cell death or causes irreversible morphological changes that impair recovery. It is recommended to begin with lower starting doses and adjust as needed. Recommended starting doses for resistance induction Note: The representative cell lines listed are provided as examples only. In practice, some cell lines may fail to develop drug resistance if drug treatment induces rapid and near-complete cell death or causes irreversible morphological changes that impair recovery. It is recommended to begin with lower starting doses and adjust as needed. Establish five cycles of drug treatment to generate resistant cells Timing: ∼1–2 months Timing: ∼1–2 months This section describes repeated drug treatment and recovery cycles designed to select for cell populations with drug resistance. Each cycle consists of acute drug exposure sufficient to induce substantial cell death (approximately 70%–90%), followed by recovery and expansion of surviving cells. Five completed cycles typically yields stable resistant populations, designated R5. Passage-matched control cells cultured without drug were prepared in parallel and are designated R0.3.Drug treatment.a.Confirm that cells are approximately 90% confluent.b.Aspirate the existing culture medium from each well.c.Add 1.5 mL of the appropriate drug-containing treatment medium to each treatment-group well of a 12-well plate.d.Add 1.5 mL complete medium to passage control well.Note: Passage control cells were TrypLE-dissociated and replated at the original seeding density in parallel with treated cells for a total of five passages (seeFigure 1as reference for plate layout). After the fifth passage, control cells, designated as R0 were expanded for killing assays. Ideally, control and treated cells should be synchronized; if control cells are ready more than two weeks earlier, they should be cryopreserved after expansion and thawed prior to killing comparisons (see troubleshooting, problem 5).e.Incubate cells at 37°C with 5% CO2.4.Treatment-recovery cycles.Note: The goal is not maximal killing, but reproducible partial killing that allows regrowth under sustained selective pressure.a.Monitor cells daily by brightfield microscopy to assess cell death, morphology, and adherence.Note: Cell death was estimated visually by brightfield microscopy to avoid additional cell manipulation that could disturb surviving adherent cells and interfere with recovery. While this method is an estimate and inherently subjective, operators should familiarize themselves with the characteristic death phenotype of their specific drug-cell line combination prior to beginning resistance induction to ensure consistent assessment across cycles.For operators who prefer a more quantitative measure, alamarBlue may be used as a non-destructive alternative following the manufacturer's instructions; however, note that alamarBlue measures metabolic activity and proliferation rather than cell death directly, and it also requires one additional manipulation step. The remaining fluorescent signals may interfere with the downstream killing assay measurement.b.Continue drug exposure until approximately 70%–90% cell death is observed, leaving a small population of surviving cells.Note: Representative morphology and estimated viability for each drug treatment (using A549 cells as an example) are shown in Figure 2.Note: Published approaches for resistance induction vary widely in the level of cell death used for selection, ranging from IC20 to IC80.5 For this protocol, a threshold of 70%–90% cell death was selected to maximize selective pressure within five treatment cycles, as lower killing levels may be insufficient to drive meaningful resistance selection within this timeframe (1–2 months). If certain cell line and drug combinations are unable to consistently achieve this level of killing without compromising recovery, the threshold may be adjusted accordingly (see troubleshooting, problems 1 and 2).c.Once the target level of cell death is reached, aspirate drug-containing medium and gently wash surviving cells twice with 1× PBS.d.Add 1.5 mL complete growth medium and allow cells to recover until ∼90% confluency is reached.e.Repeat the treatment and recovery cycle a total of five times. Cells that complete five cycles are designated R5.Note: Record the duration of drug exposure, time to recovery, and any morphological changes during each cycle. Resistant populations typically require progressively longer recovery times with successive cycles.CRITICAL: Guidance for decision-making during treatment cycles, including adjustment of drug concentration versus exposure duration, is summarized in Figure 3.CRITICAL: If 70%–90% killing cannot be achieved at the recommended starting dose despite dose escalation, and the killing curve plateaus below this threshold, the cell line may harbor intrinsic resistance and may not be suitable for this protocol.Note: A preliminary dose-response assay is recommended to assess cell line sensitivity prior to beginning resistance induction (see Note before Step 3 and Limitations).Figure 2Representative cell morphology and percentage cell death following treatmentA549 cell was used to illustrate treatment-induced morphological changes and to estimate cell death.(A) Representative morphology and percent cell death following treatment with doxorubicin.(B) Cell morphology at 72 h and corresponding percent cell death following treatment with oxaliplatin, paclitaxel, and carboplatin. Scale bar = 300 μm.Figure 3Decision tree guiding drug concentration and exposure adjustments during resistant cell generationThe schematic summarizes the primary decision point, secondary decision points, and corresponding actions where replicate wells may follow different adjustment paths within a given cycle; one condition is subsequently selected as the preferred strategy for the next cycle.Although a 3-days assessment window is indicated, cells are monitored daily, and progression through the decision tree begins immediately once the primary decision point is reached.Rep: replicate (referring to Figure 1 for two replicate wells for a single treatment); =, no change; ↓, reduce; ↑, increase. 3.Drug treatment.a.Confirm that cells are approximately 90% confluent.b.Aspirate the existing culture medium from each well.c.Add 1.5 mL of the appropriate drug-containing treatment medium to each treatment-group well of a 12-well plate.d.Add 1.5 mL complete medium to passage control well.Note: Passage control cells were TrypLE-dissociated and replated at the original seeding density in parallel with treated cells for a total of five passages (seeFigure 1as reference for plate layout). After the fifth passage, control cells, designated as R0 were expanded for killing assays. Ideally, control and treated cells should be synchronized; if control cells are ready more than two weeks earlier, they should be cryopreserved after expansion and thawed prior to killing comparisons (see troubleshooting, problem 5).e.Incubate cells at 37°C with 5% CO2. Drug treatment.a.Confirm that cells are approximately 90% confluent.b.Aspirate the existing culture medium from each well.c.Add 1.5 mL of the appropriate drug-containing treatment medium to each treatment-group well of a 12-well plate.d.Add 1.5 mL complete medium to passage control well.Note: Passage control cells were TrypLE-dissociated and replated at the original seeding density in parallel with treated cells for a total of five passages (seeFigure 1as reference for plate layout). After the fifth passage, control cells, designated as R0 were expanded for killing assays. Ideally, control and treated cells should be synchronized; if control cells are ready more than two weeks earlier, they should be cryopreserved after expansion and thawed prior to killing comparisons (see troubleshooting, problem 5).e.Incubate cells at 37°C with 5% CO2. a.Confirm that cells are approximately 90% confluent. Confirm that cells are approximately 90% confluent. b.Aspirate the existing culture medium from each well. Aspirate the existing culture medium from each well. c.Add 1.5 mL of the appropriate drug-containing treatment medium to each treatment-group well of a 12-well plate. Add 1.5 mL of the appropriate drug-containing treatment medium to each treatment-group well of a 12-well plate. d.Add 1.5 mL complete medium to passage control well.Note: Passage control cells were TrypLE-dissociated and replated at the original seeding density in parallel with treated cells for a total of five passages (seeFigure 1as reference for plate layout). After the fifth passage, control cells, designated as R0 were expanded for killing assays. Ideally, control and treated cells should be synchronized; if control cells are ready more than two weeks earlier, they should be cryopreserved after expansion and thawed prior to killing comparisons (see troubleshooting, problem 5). Add 1.5 mL complete medium to passage control well.Note: Passage control cells were TrypLE-dissociated and replated at the original seeding density in parallel with treated cells for a total of five passages (seeFigure 1as reference for plate layout). After the fifth passage, control cells, designated as R0 were expanded for killing assays. Ideally, control and treated cells should be synchronized; if control cells are ready more than two weeks earlier, they should be cryopreserved after expansion and thawed prior to killing comparisons (see troubleshooting, problem 5). Note: Passage control cells were TrypLE-dissociated and replated at the original seeding density in parallel with treated cells for a total of five passages (seeFigure 1as reference for plate layout). After the fifth passage, control cells, designated as R0 were expanded for killing assays. Ideally, control and treated cells should be synchronized; if control cells are ready more than two weeks earlier, they should be cryopreserved after expansion and thawed prior to killing comparisons (see troubleshooting, problem 5). e.Incubate cells at 37°C with 5% CO2. Incubate cells at 37°C with 5% CO2. 4.Treatment-recovery cycles.Note: The goal is not maximal killing, but reproducible partial killing that allows regrowth under sustained selective pressure.a.Monitor cells daily by brightfield microscopy to assess cell death, morphology, and adherence.Note: Cell death was estimated visually by brightfield microscopy to avoid additional cell manipulation that could disturb surviving adherent cells and interfere with recovery. While this method is an estimate and inherently subjective, operators should familiarize themselves with the characteristic death phenotype of their specific drug-cell line combination prior to beginning resistance induction to ensure consistent assessment across cycles.For operators who prefer a more quantitative measure, alamarBlue may be used as a non-destructive alternative following the manufacturer's instructions; however, note that alamarBlue measures metabolic activity and proliferation rather than cell death directly, and it also requires one additional manipulation step. The remaining fluorescent signals may interfere with the downstream killing assay measurement.b.Continue drug exposure until approximately 70%–90% cell death is observed, leaving a small population of surviving cells.Note: Representative morphology and estimated viability for each drug treatment (using A549 cells as an example) are shown in Figure 2.Note: Published approaches for resistance induction vary widely in the level of cell death used for selection, ranging from IC20 to IC80.5 For this protocol, a threshold of 70%–90% cell death was selected to maximize selective pressure within five treatment cycles, as lower killing levels may be insufficient to drive meaningful resistance selection within this timeframe (1–2 months). If certain cell line and drug combinations are unable to consistently achieve this level of killing without compromising recovery, the threshold may be adjusted accordingly (see troubleshooting, problems 1 and 2).c.Once the target level of cell death is reached, aspirate drug-containing medium and gently wash surviving cells twice with 1× PBS.d.Add 1.5 mL complete growth medium and allow cells to recover until ∼90% confluency is reached.e.Repeat the treatment and recovery cycle a total of five times. Cells that complete five cycles are designated R5.Note: Record the duration of drug exposure, time to recovery, and any morphological changes during each cycle. Resistant populations typically require progressively longer recovery times with successive cycles.CRITICAL: Guidance for decision-making during treatment cycles, including adjustment of drug concentration versus exposure duration, is summarized in Figure 3.CRITICAL: If 70%–90% killing cannot be achieved at the recommended starting dose despite dose escalation, and the killing curve plateaus below this threshold, the cell line may harbor intrinsic resistance and may not be suitable for this protocol.Note: A preliminary dose-response assay is recommended to assess cell line sensitivity prior to beginning resistance induction (see Note before Step 3 and Limitations). Treatment-recovery cycles.Note: The goal is not maximal killing, but reproducible partial killing that allows regrowth under sustained selective pressure.a.Monitor cells daily by brightfield microscopy to assess cell death, morphology, and adherence.Note: Cell death was estimated visually by brightfield microscopy to avoid additional cell manipulation that could disturb surviving adherent cells and interfere with recovery. While this method is an estimate and inherently subjective, operators should familiarize themselves with the characteristic death phenotype of their specific drug-cell line combination prior to beginning resistance induction to ensure consistent assessment across cycles.For operators who prefer a more quantitative measure, alamarBlue may be used as a non-destructive alternative following the manufacturer's instructions; however, note that alamarBlue measures metabolic activity and proliferation rather than cell death directly, and it also requires one additional manipulation step. The remaining fluorescent signals may interfere with the downstream killing assay measurement.b.Continue drug exposure until approximately 70%–90% cell death is observed, leaving a small population of surviving cells.Note: Representative morphology and estimated viability for each drug treatment (using A549 cells as an example) are shown in Figure 2.Note: Published approaches for resistance induction vary widely in the level of cell death used for selection, ranging from IC20 to IC80.5 For this protocol, a threshold of 70%–90% cell death was selected to maximize selective pressure within five treatment cycles, as lower killing levels may be insufficient to drive meaningful resistance selection within this timeframe (1–2 months). If certain cell line and drug combinations are unable to consistently achieve this level of killing without compromising recovery, the threshold may be adjusted accordingly (see troubleshooting, problems 1 and 2).c.Once the target level of cell death is reached, aspirate drug-containing medium and gently wash surviving cells twice with 1× PBS.d.Add 1.5 mL complete growth medium and allow cells to recover until ∼90% confluency is reached.e.Repeat the treatment and recovery cycle a total of five times. Cells that complete five cycles are designated R5.Note: Record the duration of drug exposure, time to recovery, and any morphological changes during each cycle. Resistant populations typically require progressively longer recovery times with successive cycles.CRITICAL: Guidance for decision-making during treatment cycles, including adjustment of drug concentration versus exposure duration, is summarized in Figure 3.CRITICAL: If 70%–90% killing cannot be achieved at the recommended starting dose despite dose escalation, and the killing curve plateaus below this threshold, the cell line may harbor intrinsic resistance and may not be suitable for this protocol.Note: A preliminary dose-response assay is recommended to assess cell line sensitivity prior to beginning resistance induction (see Note before Step 3 and Limitations). Note: The goal is not maximal killing, but reproducible partial killing that allows regrowth under sustained selective pressure. a.Monitor cells daily by brightfield microscopy to assess cell death, morphology, and adherence.Note: Cell death was estimated visually by brightfield microscopy to avoid additional cell manipulation that could disturb surviving adherent cells and interfere with recovery. While this method is an estimate and inherently subjective, operators should familiarize themselves with the characteristic death phenotype of their specific drug-cell line combination prior to beginning resistance induction to ensure consistent assessment across cycles.For operators who prefer a more quantitative measure, alamarBlue may be used as a non-destructive alternative following the manufacturer's instructions; however, note that alamarBlue measures metabolic activity and proliferation rather than cell death directly, and it also requires one additional manipulation step. The remaining fluorescent signals may interfere with the downstream killing assay measurement. Monitor cells daily by brightfield microscopy to assess cell death, morphology, and adherence.Note: Cell death was estimated visually by brightfield microscopy to avoid additional cell manipulation that could disturb surviving adherent cells and interfere with recovery. While this method is an estimate and inherently subjective, operators should familiarize themselves with the characteristic death phenotype of their specific drug-cell line combination prior to beginning resistance induction to ensure consistent assessment across cycles. Note: Cell death was estimated visually by brightfield microscopy to avoid additional cell manipulation that could disturb surviving adherent cells and interfere with recovery. While this method is an estimate and inherently subjective, operators should familiarize themselves with the characteristic death phenotype of their specific drug-cell line combination prior to beginning resistance induction to ensure consistent assessment across cycles. For operators who prefer a more quantitative measure, alamarBlue may be used as a non-destructive alternative following the manufacturer's instructions; however, note that alamarBlue measures metabolic activity and proliferation rather than cell death directly, and it also requires one additional manipulation step. The remaining fluorescent signals may interfere with the downstream killing assay measurement. b.Continue drug exposure until approximately 70%–90% cell death is observed, leaving a small population of surviving cells.Note: Representative morphology and estimated viability for each drug treatment (using A549 cells as an example) are shown in Figure 2.Note: Published approaches for resistance induction vary widely in the level of cell death used for selection, ranging from IC20 to IC80.5 For this protocol, a threshold of 70%–90% cell death was selected to maximize selective pressure within five treatment cycles, as lower killing levels may be insufficient to drive meaningful resistance selection within this timeframe (1–2 months). If certain cell line and drug combinations are unable to consistently achieve this level of killing without compromising recovery, the threshold may be adjusted accordingly (see troubleshooting, problems 1 and 2). Continue drug exposure until approximately 70%–90% cell death is observed, leaving a small population of surviving cells.Note: Representative morphology and estimated viability for each drug treatment (using A549 cells as an example) are shown in Figure 2.Note: Published approaches for resistance induction vary widely in the level of cell death used for selection, ranging from IC20 to IC80.5 For this protocol, a threshold of 70%–90% cell death was selected to maximize selective pressure within five treatment cycles, as lower killing levels may be insufficient to drive meaningful resistance selection within this timeframe (1–2 months). If certain cell line and drug combinations are unable to consistently achieve this level of killing without compromising recovery, the threshold may be adjusted accordingly (see troubleshooting, problems 1 and 2). Note: Representative morphology and estimated viability for each drug treatment (using A549 cells as an example) are shown in Figure 2. Note: Published approaches for resistance induction vary widely in the level of cell death used for selection, ranging from IC20 to IC80.5 For this protocol, a threshold of 70%–90% cell death was selected to maximize selective pressure within five treatment cycles, as lower killing levels may be insufficient to drive meaningful resistance selection within this timeframe (1–2 months). If certain cell line and drug combinations are unable to consistently achieve this level of killing without compromising recovery, the threshold may be adjusted accordingly (see troubleshooting, problems 1 and 2). c.Once the target level of cell death is reached, aspirate drug-containing medium and gently wash surviving cells twice with 1× PBS. Once the target level of cell death is reached, aspirate drug-containing medium and gently wash surviving cells twice with 1× PBS. d.Add 1.5 mL complete growth medium and allow cells to recover until ∼90% confluency is reached. Add 1.5 mL complete growth medium and allow cells to recover until ∼90% confluency is reached. e.Repeat the treatment and recovery cycle a total of five times. Cells that complete five cycles are designated R5.Note: Record the duration of drug exposure, time to recovery, and any morphological changes during each cycle. Resistant populations typically require progressively longer recovery times with successive cycles.CRITICAL: Guidance for decision-making during treatment cycles, including adjustment of drug concentration versus exposure duration, is summarized in Figure 3.CRITICAL: If 70%–90% killing cannot be achieved at the recommended starting dose despite dose escalation, and the killing curve plateaus below this threshold, the cell line may harbor intrinsic resistance and may not be suitable for this protocol.Note: A preliminary dose-response assay is recommended to assess cell line sensitivity prior to beginning resistance induction (see Note before Step 3 and Limitations). Repeat the treatment and recovery cycle a total of five times. Cells that complete five cycles are designated R5.Note: Record the duration of drug exposure, time to recovery, and any morphological changes during each cycle. Resistant populations typically require progressively longer recovery times with successive cycles.CRITICAL: Guidance for decision-making during treatment cycles, including adjustment of drug concentration versus exposure duration, is summarized in Figure 3.CRITICAL: If 70%–90% killing cannot be achieved at the recommended starting dose despite dose escalation, and the killing curve plateaus below this threshold, the cell line may harbor intrinsic resistance and may not be suitable for this protocol.Note: A preliminary dose-response assay is recommended to assess cell line sensitivity prior to beginning resistance induction (see Note before Step 3 and Limitations). Note: Record the duration of drug exposure, time to recovery, and any morphological changes during each cycle. Resistant populations typically require progressively longer recovery times with successive cycles. CRITICAL: Guidance for decision-making during treatment cycles, including adjustment of drug concentration versus exposure duration, is summarized in Figure 3. CRITICAL: If 70%–90% killing cannot be achieved at the recommended starting dose despite dose escalation, and the killing curve plateaus below this threshold, the cell line may harbor intrinsic resistance and may not be suitable for this protocol. Note: A preliminary dose-response assay is recommended to assess cell line sensitivity prior to beginning resistance induction (see Note before Step 3 and Limitations). Representative cell morphology and percentage cell death following treatment A549 cell was used to illustrate treatment-induced morphological changes and to estimate cell death. (A) Representative morphology and percent cell death following treatment with doxorubicin. (B) Cell morphology at 72 h and corresponding percent cell death following treatment with oxaliplatin, paclitaxel, and carboplatin. Scale bar = 300 μm. Decision tree guiding drug concentration and exposure adjustments during resistant cell generation The schematic summarizes the primary decision point, secondary decision points, and corresponding actions where replicate wells may follow different adjustment paths within a given cycle; one condition is subsequently selected as the preferred strategy for the next cycle. Although a 3-days assessment window is indicated, cells are monitored daily, and progression through the decision tree begins immediately once the primary decision point is reached. Rep: replicate (referring to Figure 1 for two replicate wells for a single treatment); =, no change; ↓, reduce; ↑, increase. Expand and maintain R5 cells for resistance validation Timing: ∼7–10 days Timing: ∼7–10 days This section describes the expansion of R5 cells following the completion of five treatment cycles. Cells are transferred to larger flasks and maintained under low-dose selective pressure to preserve the drug-resistant phenotype prior to downstream validation assays.5.Lift cells from each well as described in Preparation 2, Step 5.a.Transfer cells to a T75 flask to expand for killing validation.i.On Day 1, plate cells in full growth medium.ii.On Day 2, once attached, treat with cytotoxic agent at 1% of the initial treatment dose to maintain selective pressure.b.Maintain cells at 37°C with 5% CO2 under selective pressure until cultures reach 80–90% confluency.Note: Cells may be further expanded under selective pressure if required for downstream assays.CRITICAL: Cells should be maintained for downstream assays prior to freezing. Based on our experience, freeze-thaw recovery can lead to loss of resistance, as observed with MRTX1133-resistant CT26 cells which completely lost their resistance phenotype following cryopreservation and thawing. While this phenomenon may not occur in all models, we recommend validating resistance after freeze-thaw recovery before proceeding with downstream assays, and advise completing all experiments prior to cryopreservation where possible. 5.Lift cells from each well as described in Preparation 2, Step 5.a.Transfer cells to a T75 flask to expand for killing validation.i.On Day 1, plate cells in full growth medium.ii.On Day 2, once attached, treat with cytotoxic agent at 1% of the initial treatment dose to maintain selective pressure.b.Maintain cells at 37°C with 5% CO2 under selective pressure until cultures reach 80–90% confluency. Lift cells from each well as described in Preparation 2, Step 5.a.Transfer cells to a T75 flask to expand for killing validation.i.On Day 1, plate cells in full growth medium.ii.On Day 2, once attached, treat with cytotoxic agent at 1% of the initial treatment dose to maintain selective pressure.b.Maintain cells at 37°C with 5% CO2 under selective pressure until cultures reach 80–90% confluency. a.Transfer cells to a T75 flask to expand for killing validation.i.On Day 1, plate cells in full growth medium.ii.On Day 2, once attached, treat with cytotoxic agent at 1% of the initial treatment dose to maintain selective pressure. Transfer cells to a T75 flask to expand for killing validation.i.On Day 1, plate cells in full growth medium.ii.On Day 2, once attached, treat with cytotoxic agent at 1% of the initial treatment dose to maintain selective pressure. i.On Day 1, plate cells in full growth medium. On Day 1, plate cells in full growth medium. ii.On Day 2, once attached, treat with cytotoxic agent at 1% of the initial treatment dose to maintain selective pressure. On Day 2, once attached, treat with cytotoxic agent at 1% of the initial treatment dose to maintain selective pressure. b.Maintain cells at 37°C with 5% CO2 under selective pressure until cultures reach 80–90% confluency. Maintain cells at 37°C with 5% CO2 under selective pressure until cultures reach 80–90% confluency. Note: Cells may be further expanded under selective pressure if required for downstream assays. CRITICAL: Cells should be maintained for downstream assays prior to freezing. Based on our experience, freeze-thaw recovery can lead to loss of resistance, as observed with MRTX1133-resistant CT26 cells which completely lost their resistance phenotype following cryopreservation and thawing. While this phenomenon may not occur in all models, we recommend validating resistance after freeze-thaw recovery before proceeding with downstream assays, and advise completing all experiments prior to cryopreservation where possible. Validate drug resistance in R5 cells and assess cross-resistance to additional agents Timing: 4 days Timing: 4 days This section describes a quantitative killing assay used to confirm drug resistance in R5 populations relative to passage-matched R0 controls, and to evaluate cross-resistance to additional therapeutic agents. Calcein-AM fluorescence is used to assess cell viability across a range of drug concentrations, enabling calculation of EC50 values and percent killing for each condition.6.Setting up the killing plate:a.Plate R5 and R0 cells in a black 96-well plate at 20,000–40,000 cells per 100 μL per well. Include a minimum of three replicates per concentration tested.Note: Including blank control wells containing media only (no cells) is recommended to account for background fluorescence. In our experience, background signal with Calcein-AM was less than 0.5% of the total signal and did not meaningfully affect results; however, researchers should verify background levels for their specific plate reader and assay conditions.b.Incubate plates at 37°C with 5% CO2 for 24 h to allow cell attachment.c.Prepare serial dilutions of the selection agent for resistance validation and additional chemotherapeutic agents or KRAS inhibitors for cross-resistance testing in appropriate culture media. See Table 3 for recommended concentrations.Note: It is recommended to confirm resistance to the selecting agent prior to assessing cross-resistance.Table 3Recommended concentration ranges for resistance and cross-resistance killing assaysCytotoxic drugsRecommended testing range for drug resistanceRecommended testing range for cross-resistanceDoxorubicin0–50 μM0–100 μMPaclitaxel0–50 μM0–100 μMCarboplatin0–200 μM0–400 μMOxaliplatin0–100 μM0–200 μMMRTX11330–10 μM0–100 μMAMG-5100–10 μM0–100 μMNote: To determine EC50 values, an initial broad dose-response curve using a 1:3 serial dilution is recommended. For confirmation and improved curve resolution, a secondary assay using a narrower concentration window with 1:2 dilutions may be performed.d.Add 100 μL of each drug dilution to the corresponding wells.e.Incubate at 37°C with 5% CO2 for 72 h.7.Killing evaluation:a.Prepare Calcein-AM solution.i.Dilute 1:250 in HBSS supplemented with calcium and magnesium buffer (6 μM final concentration; HBSS-Ca-Mg).Note: Any suitable cytotoxicity readout may be used. Calcein-AM was selected here due to its low cost and ease of quantifying of viable cells.b.Remove treatment solution by dumping media.c.Add 100 μL of Calcein-AM solution using multi-channel pipette.d.Incubate for 40 minutes at 37°C with cell line preferred CO2 level, protected from light.e.Remove Calcein-AM solution by dumping.Note: To remove Calcein-AM solution, hold the plate by the long edge, invert firmly three times, rotate 180°, and invert two more times. Blot on absorbent paper to remove residual liquid. A 96-well aspirator may also be used, taking care not to disturb the cell monolayer.f.Add 100 μL of HBSS-Ca-Mg buffer before measuring fluorescence.g.Measure fluorescence at excitation/emission of 485nm/520nm using any fluorescence plate reader capable of these settings.Note: A Varioskan LUX plate reader was used in this study. When using a different instrument, background fluorescence should be verified. If background signal exceeds 0.5%, include blank control wells (media only, no cells) and subtract the average blank fluorescence from all sample readings prior to calculating percent killing in Step 14.8.Killing calculations:a.Calculate average fluorescence signal for no drug control wells.b.Use the equation %killing = (1- (fluorescence for each condition/mean fluorescence signal of no drug control)) × 100%.c.EC50 can be calculated in GraphPad Prism using nonlinear regression→ [agonist] vs. response –Variable slope (four parameters). Set bottom constraint equal to 0. 6.Setting up the killing plate:a.Plate R5 and R0 cells in a black 96-well plate at 20,000–40,000 cells per 100 μL per well. Include a minimum of three replicates per concentration tested.Note: Including blank control wells containing media only (no cells) is recommended to account for background fluorescence. In our experience, background signal with Calcein-AM was less than 0.5% of the total signal and did not meaningfully affect results; however, researchers should verify background levels for their specific plate reader and assay conditions.b.Incubate plates at 37°C with 5% CO2 for 24 h to allow cell attachment.c.Prepare serial dilutions of the selection agent for resistance validation and additional chemotherapeutic agents or KRAS inhibitors for cross-resistance testing in appropriate culture media. See Table 3 for recommended concentrations.Note: It is recommended to confirm resistance to the selecting agent prior to assessing cross-resistance.Table 3Recommended concentration ranges for resistance and cross-resistance killing assaysCytotoxic drugsRecommended testing range for drug resistanceRecommended testing range for cross-resistanceDoxorubicin0–50 μM0–100 μMPaclitaxel0–50 μM0–100 μMCarboplatin0–200 μM0–400 μMOxaliplatin0–100 μM0–200 μMMRTX11330–10 μM0–100 μMAMG-5100–10 μM0–100 μMNote: To determine EC50 values, an initial broad dose-response curve using a 1:3 serial dilution is recommended. For confirmation and improved curve resolution, a secondary assay using a narrower concentration window with 1:2 dilutions may be performed.d.Add 100 μL of each drug dilution to the corresponding wells.e.Incubate at 37°C with 5% CO2 for 72 h. Setting up the killing plate:a.Plate R5 and R0 cells in a black 96-well plate at 20,000–40,000 cells per 100 μL per well. Include a minimum of three replicates per concentration tested.Note: Including blank control wells containing media only (no cells) is recommended to account for background fluorescence. In our experience, background signal with Calcein-AM was less than 0.5% of the total signal and did not meaningfully affect results; however, researchers should verify background levels for their specific plate reader and assay conditions.b.Incubate plates at 37°C with 5% CO2 for 24 h to allow cell attachment.c.Prepare serial dilutions of the selection agent for resistance validation and additional chemotherapeutic agents or KRAS inhibitors for cross-resistance testing in appropriate culture media. See Table 3 for recommended concentrations.Note: It is recommended to confirm resistance to the selecting agent prior to assessing cross-resistance.Table 3Recommended concentration ranges for resistance and cross-resistance killing assaysCytotoxic drugsRecommended testing range for drug resistanceRecommended testing range for cross-resistanceDoxorubicin0–50 μM0–100 μMPaclitaxel0–50 μM0–100 μMCarboplatin0–200 μM0–400 μMOxaliplatin0–100 μM0–200 μMMRTX11330–10 μM0–100 μMAMG-5100–10 μM0–100 μMNote: To determine EC50 values, an initial broad dose-response curve using a 1:3 serial dilution is recommended. For confirmation and improved curve resolution, a secondary assay using a narrower concentration window with 1:2 dilutions may be performed.d.Add 100 μL of each drug dilution to the corresponding wells.e.Incubate at 37°C with 5% CO2 for 72 h. a.Plate R5 and R0 cells in a black 96-well plate at 20,000–40,000 cells per 100 μL per well. Include a minimum of three replicates per concentration tested.Note: Including blank control wells containing media only (no cells) is recommended to account for background fluorescence. In our experience, background signal with Calcein-AM was less than 0.5% of the total signal and did not meaningfully affect results; however, researchers should verify background levels for their specific plate reader and assay conditions. Plate R5 and R0 cells in a black 96-well plate at 20,000–40,000 cells per 100 μL per well. Include a minimum of three replicates per concentration tested.Note: Including blank control wells containing media only (no cells) is recommended to account for background fluorescence. In our experience, background signal with Calcein-AM was less than 0.5% of the total signal and did not meaningfully affect results; however, researchers should verify background levels for their specific plate reader and assay conditions. Note: Including blank control wells containing media only (no cells) is recommended to account for background fluorescence. In our experience, background signal with Calcein-AM was less than 0.5% of the total signal and did not meaningfully affect results; however, researchers should verify background levels for their specific plate reader and assay conditions. b.Incubate plates at 37°C with 5% CO2 for 24 h to allow cell attachment. Incubate plates at 37°C with 5% CO2 for 24 h to allow cell attachment. c.Prepare serial dilutions of the selection agent for resistance validation and additional chemotherapeutic agents or KRAS inhibitors for cross-resistance testing in appropriate culture media. See Table 3 for recommended concentrations.Note: It is recommended to confirm resistance to the selecting agent prior to assessing cross-resistance.Table 3Recommended concentration ranges for resistance and cross-resistance killing assaysCytotoxic drugsRecommended testing range for drug resistanceRecommended testing range for cross-resistanceDoxorubicin0–50 μM0–100 μMPaclitaxel0–50 μM0–100 μMCarboplatin0–200 μM0–400 μMOxaliplatin0–100 μM0–200 μMMRTX11330–10 μM0–100 μMAMG-5100–10 μM0–100 μMNote: To determine EC50 values, an initial broad dose-response curve using a 1:3 serial dilution is recommended. For confirmation and improved curve resolution, a secondary assay using a narrower concentration window with 1:2 dilutions may be performed. Prepare serial dilutions of the selection agent for resistance validation and additional chemotherapeutic agents or KRAS inhibitors for cross-resistance testing in appropriate culture media. See Table 3 for recommended concentrations.Note: It is recommended to confirm resistance to the selecting agent prior to assessing cross-resistance.Table 3Recommended concentration ranges for resistance and cross-resistance killing assaysCytotoxic drugsRecommended testing range for drug resistanceRecommended testing range for cross-resistanceDoxorubicin0–50 μM0–100 μMPaclitaxel0–50 μM0–100 μMCarboplatin0–200 μM0–400 μMOxaliplatin0–100 μM0–200 μMMRTX11330–10 μM0–100 μMAMG-5100–10 μM0–100 μMNote: To determine EC50 values, an initial broad dose-response curve using a 1:3 serial dilution is recommended. For confirmation and improved curve resolution, a secondary assay using a narrower concentration window with 1:2 dilutions may be performed. Note: It is recommended to confirm resistance to the selecting agent prior to assessing cross-resistance. Table 3Recommended concentration ranges for resistance and cross-resistance killing assaysCytotoxic drugsRecommended testing range for drug resistanceRecommended testing range for cross-resistanceDoxorubicin0–50 μM0–100 μMPaclitaxel0–50 μM0–100 μMCarboplatin0–200 μM0–400 μMOxaliplatin0–100 μM0–200 μMMRTX11330–10 μM0–100 μMAMG-5100–10 μM0–100 μMNote: To determine EC50 values, an initial broad dose-response curve using a 1:3 serial dilution is recommended. For confirmation and improved curve resolution, a secondary assay using a narrower concentration window with 1:2 dilutions may be performed. Recommended concentration ranges for resistance and cross-resistance killing assays Note: To determine EC50 values, an initial broad dose-response curve using a 1:3 serial dilution is recommended. For confirmation and improved curve resolution, a secondary assay using a narrower concentration window with 1:2 dilutions may be performed. d.Add 100 μL of each drug dilution to the corresponding wells. Add 100 μL of each drug dilution to the corresponding wells. e.Incubate at 37°C with 5% CO2 for 72 h. Incubate at 37°C with 5% CO2 for 72 h. 7.Killing evaluation:a.Prepare Calcein-AM solution.i.Dilute 1:250 in HBSS supplemented with calcium and magnesium buffer (6 μM final concentration; HBSS-Ca-Mg).Note: Any suitable cytotoxicity readout may be used. Calcein-AM was selected here due to its low cost and ease of quantifying of viable cells.b.Remove treatment solution by dumping media.c.Add 100 μL of Calcein-AM solution using multi-channel pipette.d.Incubate for 40 minutes at 37°C with cell line preferred CO2 level, protected from light.e.Remove Calcein-AM solution by dumping.Note: To remove Calcein-AM solution, hold the plate by the long edge, invert firmly three times, rotate 180°, and invert two more times. Blot on absorbent paper to remove residual liquid. A 96-well aspirator may also be used, taking care not to disturb the cell monolayer.f.Add 100 μL of HBSS-Ca-Mg buffer before measuring fluorescence.g.Measure fluorescence at excitation/emission of 485nm/520nm using any fluorescence plate reader capable of these settings.Note: A Varioskan LUX plate reader was used in this study. When using a different instrument, background fluorescence should be verified. If background signal exceeds 0.5%, include blank control wells (media only, no cells) and subtract the average blank fluorescence from all sample readings prior to calculating percent killing in Step 14. Killing evaluation:a.Prepare Calcein-AM solution.i.Dilute 1:250 in HBSS supplemented with calcium and magnesium buffer (6 μM final concentration; HBSS-Ca-Mg).Note: Any suitable cytotoxicity readout may be used. Calcein-AM was selected here due to its low cost and ease of quantifying of viable cells.b.Remove treatment solution by dumping media.c.Add 100 μL of Calcein-AM solution using multi-channel pipette.d.Incubate for 40 minutes at 37°C with cell line preferred CO2 level, protected from light.e.Remove Calcein-AM solution by dumping.Note: To remove Calcein-AM solution, hold the plate by the long edge, invert firmly three times, rotate 180°, and invert two more times. Blot on absorbent paper to remove residual liquid. A 96-well aspirator may also be used, taking care not to disturb the cell monolayer.f.Add 100 μL of HBSS-Ca-Mg buffer before measuring fluorescence.g.Measure fluorescence at excitation/emission of 485nm/520nm using any fluorescence plate reader capable of these settings.Note: A Varioskan LUX plate reader was used in this study. When using a different instrument, background fluorescence should be verified. If background signal exceeds 0.5%, include blank control wells (media only, no cells) and subtract the average blank fluorescence from all sample readings prior to calculating percent killing in Step 14. a.Prepare Calcein-AM solution.i.Dilute 1:250 in HBSS supplemented with calcium and magnesium buffer (6 μM final concentration; HBSS-Ca-Mg).Note: Any suitable cytotoxicity readout may be used. Calcein-AM was selected here due to its low cost and ease of quantifying of viable cells. Prepare Calcein-AM solution.i.Dilute 1:250 in HBSS supplemented with calcium and magnesium buffer (6 μM final concentration; HBSS-Ca-Mg).Note: Any suitable cytotoxicity readout may be used. Calcein-AM was selected here due to its low cost and ease of quantifying of viable cells. i.Dilute 1:250 in HBSS supplemented with calcium and magnesium buffer (6 μM final concentration; HBSS-Ca-Mg).Note: Any suitable cytotoxicity readout may be used. Calcein-AM was selected here due to its low cost and ease of quantifying of viable cells. Dilute 1:250 in HBSS supplemented with calcium and magnesium buffer (6 μM final concentration; HBSS-Ca-Mg).Note: Any suitable cytotoxicity readout may be used. Calcein-AM was selected here due to its low cost and ease of quantifying of viable cells. Note: Any suitable cytotoxicity readout may be used. Calcein-AM was selected here due to its low cost and ease of quantifying of viable cells. b.Remove treatment solution by dumping media. Remove treatment solution by dumping media. c.Add 100 μL of Calcein-AM solution using multi-channel pipette. Add 100 μL of Calcein-AM solution using multi-channel pipette. d.Incubate for 40 minutes at 37°C with cell line preferred CO2 level, protected from light. Incubate for 40 minutes at 37°C with cell line preferred CO2 level, protected from light. e.Remove Calcein-AM solution by dumping.Note: To remove Calcein-AM solution, hold the plate by the long edge, invert firmly three times, rotate 180°, and invert two more times. Blot on absorbent paper to remove residual liquid. A 96-well aspirator may also be used, taking care not to disturb the cell monolayer. Remove Calcein-AM solution by dumping.Note: To remove Calcein-AM solution, hold the plate by the long edge, invert firmly three times, rotate 180°, and invert two more times. Blot on absorbent paper to remove residual liquid. A 96-well aspirator may also be used, taking care not to disturb the cell monolayer. Note: To remove Calcein-AM solution, hold the plate by the long edge, invert firmly three times, rotate 180°, and invert two more times. Blot on absorbent paper to remove residual liquid. A 96-well aspirator may also be used, taking care not to disturb the cell monolayer. f.Add 100 μL of HBSS-Ca-Mg buffer before measuring fluorescence. Add 100 μL of HBSS-Ca-Mg buffer before measuring fluorescence. g.Measure fluorescence at excitation/emission of 485nm/520nm using any fluorescence plate reader capable of these settings.Note: A Varioskan LUX plate reader was used in this study. When using a different instrument, background fluorescence should be verified. If background signal exceeds 0.5%, include blank control wells (media only, no cells) and subtract the average blank fluorescence from all sample readings prior to calculating percent killing in Step 14. Measure fluorescence at excitation/emission of 485nm/520nm using any fluorescence plate reader capable of these settings.Note: A Varioskan LUX plate reader was used in this study. When using a different instrument, background fluorescence should be verified. If background signal exceeds 0.5%, include blank control wells (media only, no cells) and subtract the average blank fluorescence from all sample readings prior to calculating percent killing in Step 14. Note: A Varioskan LUX plate reader was used in this study. When using a different instrument, background fluorescence should be verified. If background signal exceeds 0.5%, include blank control wells (media only, no cells) and subtract the average blank fluorescence from all sample readings prior to calculating percent killing in Step 14. 8.Killing calculations:a.Calculate average fluorescence signal for no drug control wells.b.Use the equation %killing = (1- (fluorescence for each condition/mean fluorescence signal of no drug control)) × 100%.c.EC50 can be calculated in GraphPad Prism using nonlinear regression→ [agonist] vs. response –Variable slope (four parameters). Set bottom constraint equal to 0. Killing calculations:a.Calculate average fluorescence signal for no drug control wells.b.Use the equation %killing = (1- (fluorescence for each condition/mean fluorescence signal of no drug control)) × 100%.c.EC50 can be calculated in GraphPad Prism using nonlinear regression→ [agonist] vs. response –Variable slope (four parameters). Set bottom constraint equal to 0. a.Calculate average fluorescence signal for no drug control wells. Calculate average fluorescence signal for no drug control wells. b.Use the equation %killing = (1- (fluorescence for each condition/mean fluorescence signal of no drug control)) × 100%. Use the equation %killing = (1- (fluorescence for each condition/mean fluorescence signal of no drug control)) × 100%. c.EC50 can be calculated in GraphPad Prism using nonlinear regression→ [agonist] vs. response –Variable slope (four parameters). Set bottom constraint equal to 0. EC50 can be calculated in GraphPad Prism using nonlinear regression→ [agonist] vs. response –Variable slope (four parameters). Set bottom constraint equal to 0. Expected outcomes Over successive cycles, surviving cells are expected to demonstrate increased tolerance to drug exposure, indicating the establishment of populations with drug resistance (Table 4).Table 4Summary of generating A549 cells with resistance to paclitaxelCycle numberTreatment concentrationTreatment durationCell death observed (%)Decision110 μM72 h∼90%Next cycle, maintain the same dose and time210 μM72 h∼90%Next cycle, maintain the same dose and time310 μM72 h∼80%Next cycle, maintain the same dose and time410 μM72 h∼60%Next cycle, increase dose by 2×520 μM72 h∼70%Ready to lift for expansion Table 4Summary of generating A549 cells with resistance to paclitaxelCycle numberTreatment concentrationTreatment durationCell death observed (%)Decision110 μM72 h∼90%Next cycle, maintain the same dose and time210 μM72 h∼90%Next cycle, maintain the same dose and time310 μM72 h∼80%Next cycle, maintain the same dose and time410 μM72 h∼60%Next cycle, increase dose by 2×520 μM72 h∼70%Ready to lift for expansion Summary of generating A549 cells with resistance to paclitaxel After five treatment-recovery cycles, standardized killing assays were performed to evaluate whether resistant cells (R5) exhibited reduced sensitivity to the selecting agent. Compared with passage-matched control cells, R5 populations maintained higher viability across a range of drug concentrations, confirming functional drug resistance. This phenotype is illustrated in paclitaxel-treated A549 cells, where PTX R5 cells showed a clear reduction in sensitivity to paclitaxel relative to controls (Figure 4A).Figure 4Representative killing curves for resistance and cross-resistance testing. A549 cells were subjected to five cycles of paclitaxel (PTX) treatment, followed by resistance validation against PTX(A) and cross-resistance testing using oxaliplatin (OXP), carboplatin (CP), and doxorubicin (DOX) (B).n = 3–4/group per dose. Results are mean ± SEM. Representative killing curves for resistance and cross-resistance testing. A549 cells were subjected to five cycles of paclitaxel (PTX) treatment, followed by resistance validation against PTX (A) and cross-resistance testing using oxaliplatin (OXP), carboplatin (CP), and doxorubicin (DOX) (B). n = 3–4/group per dose. Results are mean ± SEM. In some cases, resistance to the selecting agent was accompanied by cross-resistance to additional therapeutics. As shown in Figure 4B, PTX R5 cells exhibited reduced sensitivity to doxorubicin (DOX), a chemotherapeutic agent with a distinct primary mechanism of action. Although these agents differ mechanistically, cross-resistance between paclitaxel and doxorubicin has been reported previously and may arise from shared cell-intrinsic resistance mechanisms, such as adaptive stress-response pathways.11 This protocol is designed to be practical, scalable, and broadly applicable. The five-cycle framework can be completed within 1–2 months, offering a rapid turnaround compared to classical stepwise dose-escalation approaches that may require several months. The protocol has been validated across four standard-of-care chemotherapies and two KRAS inhibitors in multiple human and murine cancer cell lines, demonstrating its versatility across drug classes and cellular contexts. As such, it can serve as a starting point for researchers working with other cytotoxic agents or cell lines not listed here. Beyond compound screening, the drug-resistant R5 populations generated by this protocol can serve as a resource for downstream mechanistic studies. Observable features during resistance generation, including progressive changes in drug tolerance and morphological shifts consistent with epithelial-mesenchymal transition, may provide preliminary indicators of the resistance trajectory. With appropriate follow-up tools such as clonal analysis or mutational profiling, researchers can further isolate and characterize intrinsic or acquired resistant subpopulations, making this protocol a versatile platform for studying drug resistance biology. See Gujar et al. 2025 for more representative resistance and cross-resistance data. Limitations This workflow is optimized for adherent cell lines, where drug addition, washout, and medium replacement can be performed without centrifugation, enabling selective removal of dead and dying cells by aspiration. When applied to suspension cell lines, additional centrifugation steps are required to retain viable cells; however, dead or dying cells may co-pellet with live cells, reducing the precision of selection. As a result, selection pressure may be difficult to control in suspension cultures, and additional optimization (e.g., dead-cell removal or viability gating) would be required. It is important to note that the resistance induction approach described here, which begins at concentrations inducing 70%–90% cell death, differs from classical stepwise dose-escalation protocols that start at approximately sub-IC50 concentrations and gradually increase over several months.5 While stepwise escalation may better distinguish truly acquired resistance from pre-existing resistant subclones (intrinsic), it requires significantly longer timelines and may not be practical for systematic cross-resistance screening across multiple agents and cell lines, which is one important goal for this protocol. This workflow produces heterogeneous “R5” populations shaped by treatment-induced depletion and subsequent regrowth. In other words, the R5 populations generated by this protocol have not been formally validated as models of purely acquired resistance through clonal analysis, mutational profiling, or long-term resistance stability testing upon drug withdrawal. The R5 populations should therefore be considered drug-resistant models that may encompass both intrinsic and acquired resistance mechanisms. Further validation is required to confirm the nature of resistance in specific experimental contexts. Additionally, the morphological changes observed during resistance induction, including cell flattening and spindle-like morphology (see Figure 5), are consistent with epithelial-mesenchymal transition, a phenotype associated with acquired drug resistance.14,15 Whether these changes are reversible upon drug withdrawal, and whether resistance is maintained in the absence of drug treatment, are important questions that warrant further investigation. Validation through long-term drug-free culture, assessment of resistance stability, and identification of new mutations in R5 populations would provide stronger evidence for truly acquired resistance and are recommended for studies requiring mechanistic conclusions.Figure 5Treatment-induced morphological changes observed during resistance developmentRepresentative images show morphological changes observed during drug selection.(A) Paclitaxel-treated A549 cells exhibit a flattened, enlarged morphology.(B) Carboplatin-treated CT26 cells display an elongated, spindle-like morphology. Scale bar = 300 μm. Treatment-induced morphological changes observed during resistance development Representative images show morphological changes observed during drug selection. (A) Paclitaxel-treated A549 cells exhibit a flattened, enlarged morphology. (B) Carboplatin-treated CT26 cells display an elongated, spindle-like morphology. Scale bar = 300 μm. The selection trigger of approximately 70%–90% cell death is determined by brightfield assessment and may vary depending on operator judgment, cell line morphology, and drug-specific death phenotypes (e.g., detachment, rounding, etc). While this approach minimizes cell manipulation and avoids disturbing surviving adherent cells, it is inherently subjective. Reagent-based assays such as alamarBlue may provide a more objective measure; however, alamarBlue reflects metabolic activity and proliferation rather than cell death directly, and its addition introduces an extra manipulation step that may interfere with the recovery phase. The Calcein-AM 72 hour killing assay is robust for viability but can be influenced by dye loading/efflux differences, metabolic state, and cell density effects. Some resistance phenotypes (slow-cycling, senescent) may appear “alive” but not proliferative; complementary assays (e.g., long-term outgrowth/colony formation) can be informative. Troubleshooting Problem 1 Excessive cell death occurs rapidly (<24 h) following drug exposure (Major Step 4). Potential solution The initial drug concentration may exceed the tolerance of the tested cell line, resulting in acute cytotoxicity rather than partial selection. Reduce the starting dose by 2–5-fold, or as indicated in publicly available data, and repeat the first cycle while keeping the exposure duration constant. Performing a preliminary 72 hour dose-response assay (e.g., using Calcein-AM) to estimate the EC50 for the specific cell line can help identify a starting concentration that reproducibly yields ∼70%–90% killing. Problem 2 Treated cells fail to recover to ∼90% confluency after drug washout (Major Step 4). Potential solution Failure to recover typically reflects excessive cumulative stress rather than an inability to develop drug resistance. As illustrated in Figure 3, leverage duplicate treatment wells to test alternative adjustment strategies within the same cycle. In one replicate, reduce the duration of drug exposure while maintaining the same concentration; in the other replicate, decrease the drug concentration by more than two-fold while maintaining the original exposure duration. Allow both conditions to recover and select the strategy that supports reproducible regrowth for the next cycle. Ensure that recovery medium is fully supplemented and freshly prepared and avoid disturbing surviving cells during the early recovery phase. If recovery is extremely slow or appears stalled, gently lift the cells and replate them into a smaller well format (e.g., 48-well plate) to facilitate recovery and expansion. Problem 3 During resistance induction, cells may undergo noticeable morphological changes, including alterations in size, shape, and adherence (Figure 5), which can complicate interpretation of cell health and treatment response (Major Step 4). Potential solution Morphological changes may reflect alterations in physical appearance such as cell flattening and enlargement or the development of spindle-like shape. Monitor cell morphology daily and document changes across cycles. If pronounced abnormalities persist over multiple cycles, extend the drug-free recovery phase to allow population stabilization before re-treatment. If morphology remains unstable, consider lowering selective pressure or restarting the selection using a reduced starting dose. Resistant populations should exhibit reproducible morphology across passages prior to downstream killing assays. Problem 4 Loss of resistance phenotype after drug withdrawal or freeze thaw following liquid N2 storage (Major Step 5). Potential solution Some resistance states are partially reversible and require continued selective pressure for maintenance. After completion of five treatment cycles, maintain R5 cells under low-dose drug pressure (see Major Step 11), typically ∼1% of the original treatment concentration, during expansion. Avoid prolonged culture in drug-free conditions prior to validation. Freezing resistant populations before validation is discouraged, as freeze-thaw recovery may lead to loss of resistance due to population heterogeneity. If resistance is lost, the selection process must be re-established. Problem 5 Timing mismatch between passage-matched control (R0) cells and treated cells (Major Step 6). Potential solution Differences in recovery times between treatment cycles can cause control cells to reach experimental readiness earlier than treated cells. To maintain synchronization, passage control cells only at the start of each treatment cycle and seed them at reduced density so they remain sub-confluent throughout the cycle. If control cells reach expansion readiness more than two weeks before treated cells, cryopreserve control cells after expansion and thaw them immediately prior to setting up killing assays. This ensures comparable passage number and minimizes confounding effects of prolonged culture. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Chang Cui (ccui@onchillespharma.com). Technical contact Technical inquiries should be directed to Chang Cui (ccui@onchillespharma.com). Materials availability This study did not generate new unique reagents. Data and code availability This study does not report original code or datasets. Additional information required to reanalyze the data is available from the lead contact upon request. Acknowledgments This work was supported by private funds from Onchilles Pharma Inc. We thank Court Turner for funding acquisition; Peter Haberz for acquisition of reagents, equipment, and contract management; and Carmen White for financial management. Author contributions Conceptualization, L.B., C.C., and N.M.; methodology, N.M., C.C., and L.B.; formal analysis, N.M. and C.C.; investigation, N.M. and C.C.; writing – original draft, N.M. and C.C.; manuscript editing, N.M., C.C., L.B., R.G., and M.F.; supervision, L.B. Declaration of interests This research was performed at Onchilles Pharma Inc., a privately held biotechnology company in San Diego, CA, USA. L.B. is a co-founder, board member, chief scientific officer, and stockholder of Onchilles Pharma Inc. N.M., C.C., R.G., and M.F. are employees of Onchilles Pharma Inc. with stock options.